The Cytogenetic Landscape of Pediatric Chronic Myeloid Leukemia Diagnosed in Chronic Phase.

Philadelphia chromosome additional chromosomal aberrations chronic myeloid leukemia complex karyotype cytogenetic response molecular response pediatric chronic myeloid leukemia tyrosine kinase inhibitor treatment variant translocations

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
28 Mar 2022
Historique:
received: 06 03 2022
revised: 23 03 2022
accepted: 25 03 2022
entrez: 12 4 2022
pubmed: 13 4 2022
medline: 13 4 2022
Statut: epublish

Résumé

Philadelphia chromosome-positive chronic myeloid leukemia (CML) is cytogenetically characterized by the classic translocation t(9;22)(q34;q11), whereas additional non-Philadelphia aberrations (nPhAs) have been studied extensively in adult patients with CML, knowledge on nPhAs in pediatric patients with CML is still sparse. Here, we have determined nPhAs in a cohort of 161 patients younger than 18 years diagnosed with chronic phase CML and consecutively enrolled in the German national CML-PAED-II registry. In 150 cases (93%), an informative cytogenetic analysis had been performed at diagnosis. In total, 21 individuals (13%) showed nPhAs. Of these, 12 (8%) had a variant translocation, 4 (3%) additional chromosomal aberrations (ACAs) and 5 (3%) harbored a complex karyotype. Chromosome 15 was recurrently involved in variant translocations. No significant impact of the cytogenetic subgroup on the time point of cytogenetic response was observed. Patients with a complex karyotype showed an inferior molecular response compared to patients carrying the classic translocation t(9;22)(q34;q11), variant translocations or ACAs. No significant differences in the probability of progression-free survival and overall survival was found between patients with nPhAs and patients with the classic Philadelphia translocation only. Our results highlight the distinct biology of pediatric CML and underline the need for joint international efforts to acquire more data on the disease pathogenesis in this age group.

Identifiants

pubmed: 35406484
pii: cancers14071712
doi: 10.3390/cancers14071712
pmc: PMC8997049
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Federal Ministry of Education and Research
ID : 01GM1911A

Références

Nature. 1973 Jun 1;243(5405):290-3
pubmed: 4126434
Cancer. 2017 Sep 15;123(18):3609-3616
pubmed: 28497898
Cancers (Basel). 2021 Feb 14;13(4):
pubmed: 33672937
Blood. 2011 Jun 23;117(25):6793-800
pubmed: 21447834
Blood. 2012 Jul 26;120(4):761-7
pubmed: 22692507
Br J Haematol. 2021 May;193(3):613-618
pubmed: 33690887
J Cell Mol Med. 2019 Aug;23(8):4955-4961
pubmed: 31199062
Blood. 2011 Jun 23;117(25):6741-2
pubmed: 21700778
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Blood. 2006 Jul 1;108(1):28-37
pubmed: 16522812
Haematologica. 2012 Jul;97(7):1029-35
pubmed: 22271898
Cancer Genet Cytogenet. 2007 Mar;173(2):97-106
pubmed: 17321324
Hum Genet. 1990 Oct;85(6):565-8
pubmed: 2227945
Blood. 2016 Jun 2;127(22):2742-50
pubmed: 27006386
Leukemia. 2020 Apr;34(4):966-984
pubmed: 32127639
Leuk Lymphoma. 1993;11 Suppl 1:11-5
pubmed: 8251885
Blood. 2016 Jun 2;127(22):2661-2
pubmed: 27257178
Blood. 2016 Jan 28;127(4):392-9
pubmed: 26511135
Blood. 2015 Oct 1;126(14):1699-706
pubmed: 26243778
Genes Chromosomes Cancer. 2012 Nov;51(11):1045-53
pubmed: 22887688
Blood. 2011 Dec 22;118(26):6760-8
pubmed: 22039253
Int J Cancer. 1976 Jul 15;18(1):24-30
pubmed: 1065618
Blood. 1999 Nov 1;94(9):3114-20
pubmed: 10556197
Ann Hematol. 2014 Jan;93(1):71-80
pubmed: 24162333
Leukemia. 2018 Jul;32(7):1657-1669
pubmed: 29925908
Leukemia. 2015 Nov;29(11):2263-6
pubmed: 25931274
Ann Oncol. 2015 Jan;26(1):185-192
pubmed: 25361995
Ann Hematol. 2015 Aug;94(8):1363-71
pubmed: 25894600

Auteurs

Axel Karow (A)

Department of Pediatrics and Adolescent Medicine, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), D-91054 Erlangen, Germany.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), D-91054 Erlangen, Germany.

Gudrun Göhring (G)

Department of Human Genetics, Hannover Medical School, D-30625 Hannover, Germany.

Stephanie Sembill (S)

Department of Pediatrics and Adolescent Medicine, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), D-91054 Erlangen, Germany.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), D-91054 Erlangen, Germany.

Friederike Lutterloh (F)

Department of Human Genetics, Hannover Medical School, D-30625 Hannover, Germany.

Fina Neuhaus (F)

Department of Human Genetics, Hannover Medical School, D-30625 Hannover, Germany.

Sara Callies (S)

Department of Human Genetics, Hannover Medical School, D-30625 Hannover, Germany.

Elke Schirmer (E)

Department of Pediatrics and Adolescent Medicine, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), D-91054 Erlangen, Germany.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), D-91054 Erlangen, Germany.

Zofia Wotschofsky (Z)

Department of Pediatrics and Adolescent Medicine, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), D-91054 Erlangen, Germany.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), D-91054 Erlangen, Germany.

Oisin Roche-Lancaster (O)

Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), D-91054 Erlangen, Germany.
Center of Medical Information and Communication Technology, University Hospital Erlangen, D-91054 Erlangen, Germany.

Meinolf Suttorp (M)

Medical Faculty, Pediatric Hematology and Oncology, Technical University, D-01307 Dresden, Germany.

Manuela Krumbholz (M)

Department of Pediatrics and Adolescent Medicine, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), D-91054 Erlangen, Germany.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), D-91054 Erlangen, Germany.

Markus Metzler (M)

Department of Pediatrics and Adolescent Medicine, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), D-91054 Erlangen, Germany.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), D-91054 Erlangen, Germany.

Classifications MeSH